211 related articles for article (PubMed ID: 32071061)
1. Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.
McCormick KD; Penrose KJ; Brumme CJ; Harrigan PR; Viana RV; Mellors JW; Parikh UM; Wallis CL
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071061
[TBL] [Abstract][Full Text] [Related]
2. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
3. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
Maïga AI; Descamps D; Morand-Joubert L; Malet I; Derache A; Cisse M; Koita V; Akonde A; Diarra B; Wirden M; Tounkara A; Verlinden Y; Katlama C; Costagliola D; Masquelier B; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2010 Feb; 54(2):728-33. PubMed ID: 20008779
[TBL] [Abstract][Full Text] [Related]
4. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
[TBL] [Abstract][Full Text] [Related]
5. Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity.
Agneskog E; Nowak P; Maijgren Steffensson C; Casadellà M; Noguera-Julian M; Paredes R; Källander CF; Sönnerborg A
PLoS One; 2014; 9(7):e101508. PubMed ID: 25000302
[TBL] [Abstract][Full Text] [Related]
6. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
[TBL] [Abstract][Full Text] [Related]
7. Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.
Penrose KJ; Wallis CL; Brumme CJ; Hamanishi KA; Gordon KC; Viana RV; Harrigan PR; Mellors JW; Parikh UM
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895013
[TBL] [Abstract][Full Text] [Related]
8. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
[TBL] [Abstract][Full Text] [Related]
9. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
[TBL] [Abstract][Full Text] [Related]
10. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
11. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
Asahchop EL; Wainberg MA; Oliveira M; Xu H; Brenner BG; Moisi D; Ibanescu IR; Tremblay C
AIDS; 2013 Mar; 27(6):879-887. PubMed ID: 23262501
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG; Flandre P; Descamps D; Morand-Joubert L; Charpentier C; Izopet J; Trabaud MA; Saoudin H; Delaugerre C; Tamalet C; Cottalorda J; Bouvier-Alias M; Bettinger D; Dos Santos G; Ruffault A; Alloui C; Henquell C; Rogez S; Barin F; Signori-Schmuck A; Vallet S; Masquelier B; Calvez V;
Antimicrob Agents Chemother; 2010 Jan; 54(1):72-7. PubMed ID: 19901096
[TBL] [Abstract][Full Text] [Related]
13. Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.
Derache A; Wallis CL; Vardhanabhuti S; Bartlett J; Kumarasamy N; Katzenstein D
J Infect Dis; 2016 Jan; 213(2):250-6. PubMed ID: 26175454
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.
Asahchop EL; Oliveira M; Wainberg MA; Brenner BG; Moisi D; Toni Td; Tremblay CL
Antimicrob Agents Chemother; 2011 Feb; 55(2):600-7. PubMed ID: 21135184
[TBL] [Abstract][Full Text] [Related]
15. Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.
Penrose KJ; Brumme CJ; Scoulos-Hanson M; Hamanishi K; Gordon K; Viana RV; Wallis CL; Harrigan PR; Mellors JW; Parikh UM
Antivir Chem Chemother; 2018; 26():2040206618762985. PubMed ID: 29566538
[TBL] [Abstract][Full Text] [Related]
16. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
17. Drug susceptibility and resistance mutations after first-line failure in resource limited settings.
Wallis CL; Aga E; Ribaudo H; Saravanan S; Norton M; Stevens W; Kumarasamy N; Bartlett J; Katzenstein D;
Clin Infect Dis; 2014 Sep; 59(5):706-15. PubMed ID: 24795328
[TBL] [Abstract][Full Text] [Related]
18. Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.
Saravanan S; Kausalya B; Gomathi S; Sivamalar S; Pachamuthu B; Selvamuthu P; Pradeep A; Sunil S; Mothi SN; Smith DM; Kantor R
AIDS Res Hum Retroviruses; 2017 Jun; 33(6):567-574. PubMed ID: 27869478
[TBL] [Abstract][Full Text] [Related]
19. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.
Steegen K; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; Variava E; MacLeod W; Sanne I; Stevens WS; Carmona S
J Antimicrob Chemother; 2017 Jan; 72(1):210-219. PubMed ID: 27659733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
